It's as you've stated time and time, again...100% clerical & 0% juice. Today's 8-K, IMO, ended the revamped clerical stage and now comes the juice. I strongly suspect Dr. Koos has a rather robust pipeline of deals (licensing agreements et al), which will continue to come to fruition. A very methodical, organic growth of the company. Now, here comes the kicker...Dr. Koos stated in today's 8-K, the intent to: "1) Settle all outstanding convertible notes payable in order that the Company will have no convertible instruments outstanding." and being that we already have/know the firm: "7) Entered into two non-related party licensing agreement resulting in non-related party common-revenue of $1,905,000 being recognized in the quarter ended June 30, 2021. These licensing agreements pertain to mRNA and our checkpoint NR2F6." I expect the cash-on-hand of Regen to accumulate rapidly...
...can you say potential common-share Buy-back!
Thereafter, where would the aforementioned growth and constricting of the common-share pool see the company's valuation (pps), when/if buyout conversations are begun, in earnest!
Food (juice) for thought:) lol
RGBP
News 
Market Data 
Discover 
AI
